查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1587846

美國靜脈注射注射液市場規模、佔有率、趨勢分析報告：按產品、營養、最終用途、細分市場預測，2025-2030 年

U.S. Intravenous Solutions Market Size, Share & Trends Analysis Report By Product (TPN, PPN), By Nutrients (Carbohydrates, Vitamins & Minerals), By End-use (Home, Hospitals), And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 105 Pages | 商品交期: 2-10個工作天內

價格

美國靜脈注射輸液市場的成長與趨勢：

Grand View Research最新報告顯示，到2030年，美國靜脈注射輸液市場規模預計將達到79.1億美元，預測期內複合年成長率為7.8%。

由於疾病盛行率的增加和外科手術數量的增加，市場正在成長。人口老化更容易罹患癌症、神經系統疾病、心血管疾病和脊椎損傷等非傳染性疾病，也是市場擴張的驅動力。 2024 年 10 月，Fresenius Medical Care 宣布了一項旨在減輕透析護理中斷的措施。該公司利用其全球製造設施來提高透析液和輸注液的產量。在衛生與公共服務部的敦促下，費森尤斯醫療致力於透過改善生產策略來滿足輸液和腹膜透析 (PD) 產品的需求。

靜脈靜脈注射療法可以透過補充體內電解質平衡來有效治療嚴重脫水，特別是對於患有糖尿病或腎臟病等慢性病的人。主要治療方法是生理食鹽水，它是水和氯化鈉的混合物。含有葡萄糖、右旋糖和左旋糖等糖的溶液也是標準溶液。 2023 年 12 月，領先的輸液治療和技術公司 Baxter 與西北醫學院合作完成了輸液袋回收試驗的第一階段。該計劃成功避免了超過 6 噸的 PVC IV 袋最終被扔進垃圾掩埋場。這些首尾相連的袋子將遍布芝加哥，展示該計劃對環境保護的貢獻。

美國靜脈注射輸液市場報告亮點：

  • 到2024年，全腸外營養（TPN）將佔總腸外營養的67.14%，因為它在為無法口服或透過胃腸道吸收的患者直接向血液提供必需營養方面發揮著重要作用。的銷售佔有率。
  • 從營養成分來看，單劑量胺基酸溶液細分市場佔據主導地位，2024年市場佔有率為31.33%。這些解決方案是根據特定患者的需求量身定做的，以確保他們獲得足夠的氨基酸來恢復和維持身體功能。
  • 維生素和礦物質領域預計在預測期內將以最快的複合年成長率成長。這些微量營養素對於各種代謝過程和整體健康至關重要，特別是對於接受 TPN 和其他形式腸外營養的患者。
  • 就最終用途而言，醫院細分市場由於其在急診環境中的重要作用，在該細分市場中佔據主導地位，到 2024 年，其市場佔有率將達到 46.0%。醫院是這個市場的重要參與者，因為它們需要穩定地為各種醫療程序（包括手術和醫療緊急情況）供應靜脈注射輸液。
  • 由於家庭治療對患者來說更加方便且更具成本效益，家庭治療的偏好日益增加，預計家庭治療領域在預測期內將以最快的複合年成長率成長。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章美國靜脈注射輸液市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 美國靜脈注射輸液市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • 管道分析

第4章美國靜脈注射注射市場：產品估算及趨勢分析

  • 美國靜脈注射輸液市場：產品儀表板
  • 美國靜脈注射輸液市場：產品變化分析
  • 美國靜脈注射輸液市場：按產品分類的收益
  • 全腸外營養（TPN）
  • 周邊腸外營養（PPN）

第5章美國靜脈注射市場：營養評估及趨勢分析

  • 美國靜脈注射輸液市場：營養儀表板
  • 美國靜脈注射市場：營養波動分析
  • 美國靜脈注射市場：以營養分類的收益
  • 碳水化合物
  • 單劑量胺基酸
  • 維生素和礦物質
  • 腸外脂肪乳劑
  • 其他

第6章美國靜脈注射注射市場：最終用途估計和趨勢分析

  • 美國靜脈注射輸液市場：最終用途儀表板
  • 美國靜脈注射輸液市場：最終用途變化分析
  • 美國靜脈注射輸液市場：依最終用途分類的收益
  • 家用
  • 醫院
  • 點滴中心

第7章 競爭格局

  • 主要製造商的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
    • 主要經銷商及通路夥伴名單
    • 主要客戶
    • 2024年主要企業市場佔有率分析
  • 公司簡介
    • Fresenius Kabi AG
    • Pfizer Inc.
    • Baxter
    • B. Braun Melsungen AG
    • JW Life Science
    • ICU Medical, Inc.
    • Grifols USA, LLC
    • Amphastar Pharmaceuticals, Inc.
    • Athenex, Inc.
    • Rockwell Medical, Inc.
    • Exela Pharma Sciences, LLC
Product Code: GVR-4-68040-286-4

U.S. Intravenous Solutions Market Growth & Trends:

The U.S. intravenous solutions market size is anticipated to reach USD 7.91 billion by 2030 and is projected to grow at a CAGR of 7.8% during the forecast period, according to a new report by Grand View Research, Inc. The market is experiencing growth due to the increasing prevalence of disease and a rise in surgical procedures. The aging population, which is more prone to non-communicable diseases such as cancer, neurological, cardiovascular disorders, and spinal injuries, is also driving market expansion. In October 2024, Fresenius Medical Care announced initiatives to mitigate disruptions in dialysis care. The company is enhancing the production of PD and IV solutions by leveraging its global production facilities. Prompted by the Department of Health & Human Services, Fresenius Medical Care is committed to meeting the demand for IV fluids and peritoneal dialysis (PD) products through improved production strategies.

IV hydration therapy effectively treats severe dehydration, especially in people with chronic conditions like diabetes or kidney diseases, by replenishing the body's electrolyte balance. The primary treatment is saline solution, water mixed with sodium chloride. Solutions with sugars like glucose, dextrose, or levulose are also standard. In December 2023, Baxter, a prominent company in infusion therapies and technologies, finished the first stage of its IV bag recycling trial in partnership with Northwestern Medicine. This program has successfully diverted over six tons of PVC IV bag material from being disposed of in landfills. If these bags were placed end to end, they would stretch across Chicago, demonstrating the project's contribution to environmental preservation.

U.S. Intravenous Solutions Market Report Highlights:

  • The total parenteral nutrition (TPN) type segment held the largest revenue share of 67.14% in 2024 due to its critical role in providing essential nutrients directly into the bloodstream for patients who cannot consume food orally or absorb nutrients through their gastrointestinal tract.
  • Based on nutrients, the single-dose amino acid solution segment dominated the segment with a market share of 31.33% in 2024 as it offers a convenient and effective means of delivering protein directly to patients. These solutions are tailored to specific patient needs, ensuring that they receive adequate amino acids necessary for recovery and maintenance of bodily functions.
  • The vitamins & minerals segment is expected to grow at the fastest CAGR over the forecast period. These micronutrients are essential for various metabolic processes and overall health, particularly in patients receiving TPN or other forms of parenteral nutrition.
  • In terms of end use, the hospitals segment dominated the segment with a market share of 46.0% in 2024 due to their critical role in acute care settings. Hospitals require a steady supply of intravenous solutions for various medical procedures, including surgeries and emergency care, making them essential players in this market.
  • The home segment is expected to grow at the fastest CAGR over the forecast period due to an increasing preference for at-home treatments, which are more convenient and cost-effective for patients.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Nutrients
    • 1.2.3. End Use
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Volume price analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Nutrients' outlook
    • 2.2.3. End use outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Intravenous Solutions Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of chronic diseases
      • 3.2.1.2. Aging population
      • 3.2.1.3. Advancements in medical technology
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High costs associated with IV therapy due to shortages
      • 3.2.2.2. Risk of complications
  • 3.3. U.S. Intravenous Solutions Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pipeline Analysis

Chapter 4. U.S. Intravenous Solutions Market: Product Estimates & Trend Analysis

  • 4.1. Global U.S. Intravenous Solutions Market: Product Dashboard
  • 4.2. Global U.S. Intravenous Solutions Market: Product Movement Analysis
  • 4.3. Global U.S. Intravenous Solutions Market by Product, Revenue
  • 4.4. Total Parenteral Nutrition (TPN)
    • 4.4.1. Total parenteral nutrition (TPN) market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.5. Peripheral Parenteral Nutrition (PPN)
    • 4.5.1. Peripheral parenteral nutrition (PPN) market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. U.S. Intravenous Solutions Market: Nutrients Estimates & Trend Analysis

  • 5.1. Global U.S. Intravenous Solutions Market: Nutrients Dashboard
  • 5.2. Global U.S. Intravenous Solutions Market: Nutrients Movement Analysis
  • 5.3. Global U.S. Intravenous Solutions Market by Nutrients, Revenue
  • 5.4. Carbohydrates
    • 5.4.1. Carbohydrates market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.5. Single Dose Amino Acids
    • 5.5.1. Single dose amino acids market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.6. Vitamins And Minerals
    • 5.6.1. Vitamins and minerals market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.7. Parenteral Lipid Emulsion
    • 5.7.1. Parenteral lipid emulsion market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.8. Others
    • 5.8.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. U.S. Intravenous Solutions Market: End Use Estimates & Trend Analysis

  • 6.1. Global U.S. Intravenous Solutions Market: End Use Dashboard
  • 6.2. Global U.S. Intravenous Solutions Market: End Use Movement Analysis
  • 6.3. Global U.S. Intravenous Solutions Market by End Use, Revenue
  • 6.4. Home
    • 6.4.1. Home market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5. Hospitals
    • 6.5.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6. Infusion Center
    • 6.6.1. Infusion center market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Manufacturers
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. Fresenius Kabi AG
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Pfizer Inc.
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Baxter
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. B. Braun Melsungen AG
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. JW Life Science
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. ICU Medical, Inc.
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Grifols USA, LLC
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Amphastar Pharmaceuticals, Inc.
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Athenex, Inc.
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Rockwell Medical, Inc.
      • 7.4.10.1. Company overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Product benchmarking
      • 7.4.10.4. Strategic initiatives
    • 7.4.11. Exela Pharma Sciences, LLC
      • 7.4.11.1. Company overview
      • 7.4.11.2. Financial performance
      • 7.4.11.3. Product benchmarking
      • 7.4.11.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. Intravenous solutions market, by type, 2018 - 2030 (USD Billion)
  • Table 3 U.S. Intravenous solutions market, by nutrients, 2018 - 2030 (USD Billion)
  • Table 4 U.S. Intravenous solutions market, by end use, 2018-2030 (USD Billion)
  • Table 5 Participant's overview
  • Table 6 Financial performance
  • Table 7 Key companies undergoing expansions
  • Table 8 Key companies undergoing acquisitions
  • Table 9 Key companies undergoing collaborations
  • Table 10 Key companies launching new products
  • Table 11 Key companies undergoing partnerships
  • Table 12 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. intravenous solutions market: market outlook
  • Fig. 9 U.S. intravenous solutions competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 U.S. intravenous solutions market driver impact
  • Fig. 14 U.S. intravenous solutions market restraint impact
  • Fig. 15 U.S. intravenous solutions: Product movement analysis
  • Fig. 16 U.S. intravenous solutions: Product outlook and key takeaways
  • Fig. 17 Total parenteral nutrition market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 18 Peripheral parenteral nutrition market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 19 U.S. intravenous solutions: Nutrients movement analysis
  • Fig. 20 U.S. intravenous solutions: Nutrients outlook and key takeaways
  • Fig. 21 Carbohydrates market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 22 Single dose amino acids market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 23 Vitamins and minerals market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 24 Parenteral lipid emulsion market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 25 Others market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 26 U.S. intravenous solutions: End use movement analysis
  • Fig. 27 U.S. intravenous solutions: End use outlook and key takeaways
  • Fig. 28 Home market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 29 Hospitals market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 30 Infusion center market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 31 Key company categorization
  • Fig. 32 Strategy mapping